|
ASH/FDA Workshop on Clinical
Endpoints in Acute Leukemia
Presented by the
American Society of Hematology and the
U.S. Food and Drug
Administration
Co-sponsored by the American Association for Cancer Research, American
Society of Clinical Oncology, and Southwest Oncology Group
Friday, June 24, 2005
8:30 a.m. – 5:00 p.m.
JW Marriott Hotel Pennsylvania Avenue
Salons F and E
1331 Pennsylvania Avenue, Washington, DC 20004
Ph: (202) 393-2000
AGENDA
8:00 am |
Continental Breakfast
Available
Registration for Public Comments |
|
|
|
|
8:30 am |
Welcome and Introductions |
Stanley L. Schrier, MD |
|
|
Richard Pazdur, MD |
8:40 am |
Purpose of Conference &
Regulatory Background |
Nancy Scher, MD
|
9:00 am |
Scope and Background of Panel |
Frederick Appelbaum, MD
|
9:10 am |
Scope of Problem /
Heterogeneity Component
|
Frederick Appelbaum, MD
|
9:30 am |
Panel Questions regarding
Heterogeneity |
Panel |
9:50 am |
Break |
|
10:00 am |
Definition of Response
Component |
Susan O’Brien, MD
|
10:20 am |
Panel Questions regarding
Definition of Response |
Panel |
10:40 am |
Minimal Residual Disease
Component |
William L. Carroll, MD
|
11:00 am |
Panel Questions regarding
Minimal Residual Disease
|
Panel |
11:20 am |
Bridge to Transplant
Component |
Robert J. Arceci, MD |
11:40 am |
Panel Questions regarding Bridge
to Transplant |
Panel |
12:00 pm |
Lunch Available for all
Registered Participants (Garden Terrace) |
|
1:00 pm |
Quality of Life Component |
Philip Breitfeld, MD |
1:20 pm |
Panel Questions regarding
Quality of Life |
Panel
|
1:40 pm |
Public Comments |
|
2:10 pm |
Chairs’ Questions to Panel |
Frederick Appelbaum,
MD Daniel
Rosenblum, MD |
Back to Top
Back to Cancer Endpoints
Date created: September 21, 2005 |
|